Previous 10 | Next 10 |
Science 37 press release (NASDAQ:SNCE): Q1 GAAP EPS of $0.35 beats by $0.61. Revenue of $18.69M (+50.2% Y/Y) beats by $3.63M. The company is reaffirming FY2022 revenue guidance of $86M to $96M vs. consensus of $91.13M. David Coman, Chief Executive Officer of Science 37 said, "With our sales p...
RESEARCH TRIANGLE PARK, N.C., May 09, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”) the Agile Clinical Trial Operating System™, today reported its financial results for the quarter ended March 31, 2022. "The first quarter of 202...
RESEARCH TRIANGLE PARK, N.C., April 25, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced it will report first quarter 2022 financial results before the market opens on Monday, May 9, 2022. Company management...
Gainers: Trevi Therapeutics (TRVI) +36%. Sunshine Biopharma (SBFM) +31%. IMAC Holdings (IMAC) +28%. Werewolf Therapeutics (HOWL) +25%. Ikena Oncology (IKNA) +22%. Losers: Aptinyx (APTX) -47%. Vapotherm (VAPO) -29%. Rite Aid (RAD) -23%. Biophytis (BPTS) -13%. Science 37 Holdings (SNC...
RESEARCH TRIANGLE PARK, N.C., March 31, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced it is fortifying its oncology and hematology research acumen by adding Shaalan Beg, M.D., M.S.C.S. to its Global Manag...
Science 37 Holdings, Inc. (SNCE) Q4 2021 Results Earnings Conference Call March 22, 2022, 08:00 AM ET Company Participants Caroline Paul - Investor Relations David Coman - Chief Executive Officer Mike Zaranek - Chief Financial Officer Conference Call Participants Charles Rhyee - Cowen Frank T...
Science 37 press release (NASDAQ:SNCE): Q4 GAAP EPS of -$0.60 misses by $0.25. Revenue of $20.37M (+82.5% Y/Y) beats by $5.59M. The company is providing guidance for the calendar year ending December 31, 2022 for total revenues between $86 and $96 million. For further details see: Scien...
RESEARCH TRIANGLE PARK, N.C., March 22, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”) the Agile Clinical Trial Operating System™, today reported its financial results for the quarter and full year ended December 31, 2021. ȁ...
RESEARCH TRIANGLE PARK, N.C., March 08, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced it will report fourth quarter and full year 2021 financial results before the market opens on Tuesday, March 22, 2022....
Gainers: Houston American Energy HUSA +157%. Imperial Petroleum IMPP +95%. Indonesia Energy Corporation INDO +74%. Camber Energy (NYSE:CEI) +49%. Nine Energy Service NINE +42%. Sunworks (NASDAQ:SUNW) +31%. Bed Bath & Beyond BBBY +28%. Eqonex EQOS +28%. Marine...
News, Short Squeeze, Breakout and More Instantly...
Science 37 Holdings Inc. Company Name:
SNCE Stock Symbol:
NASDAQ Market:
Science 37 Holdings Inc. Website:
MORRISVILLE, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Science 37 , a leader in enhancing patient access to clinical trials, disclosed the final figures resulting from its partnership with a biopharmaceutical company focused on infectious disease prevention research. Science 37 contributed ...
RESEARCH TRIANGLE PARK, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- Science 37 , a leader in enhancing patient access to clinical trials, has been added to over 20 studies that were lagging in recruitment, helping them to trend back towards their projected targets. Leveraging its proprietary ...
RESEARCH TRIANGLE PARK, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Science 37, Inc., please note that the first sentence of the second paragraph has been revised. The corrected release follows: Science 37 Holdings, Inc. , a lea...